Genscript Biotech Corporation
Genscript Biotech Corporation (GNNSF) Financial Performance & Income Statement Overview
Access detailed quarterly and annual financial reports for Genscript Biotech Corporation (GNNSF), covering cash flow, earnings, and balance sheets.
Genscript Biotech Corporation (GNNSF) Income Statement & Financial Overview
Explore comprehensive income reports for Genscript Biotech Corporation GNNSF, broken down by year and quarter.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $33.12M | $561.37M | $448.71M | $224.11M |
| Cost of Revenue | $67.98M | $254.38M | $213.95M | $106.86M |
| Gross Profit | -$34.86M | $306.99M | $234.76M | $117.25M |
| Gross Profit Ratio | -$1.05 | $0.55 | $0.52 | $0.52 |
| R&D Expenses | -$182.59M | $236.38M | $225.74M | $112.75M |
| SG&A Expenses | -$18.88M | $221.37M | $181.34M | $101.12M |
| Operating Expenses | -$194.91M | $457.76M | $407.09M | $186.53M |
| Total Costs & Expenses | -$126.94M | $712.14M | $621.03M | $293.38M |
| Interest Income | $28.89M | $0.00 | $47.32M | $16.11M |
| Interest Expense | $8.03M | $0.00 | $15.08M | $0.00 |
| Depreciation & Amortization | $28.31M | $32.84M | $38.53M | $14.47M |
| EBITDA | $188.36M | -$117.94M | -$51.70M | -$82.14M |
| EBITDA Ratio | $5.69 | -$0.21 | -$0.30 | -$0.37 |
| Operating Income | $160.05M | -$150.77M | -$172.32M | -$96.61M |
| Operating Income Ratio | $4.83 | -$0.27 | -$0.38 | -$0.43 |
| Other Income/Expenses (Net) | -$125.26M | -$54.82M | $67.04M | $43.45M |
| Income Before Tax | $34.79M | -$205.59M | -$105.29M | -$53.16M |
| Income Before Tax Ratio | $1.05 | -$0.37 | -$0.23 | -$0.24 |
| Income Tax Expense | -$7.07M | $10.04M | $3.04M | $1.52M |
| Net Income | $3.14B | -$175.12M | -$1.90M | -$948000.00 |
| Net Income Ratio | $94.73 | -$0.31 | -$0.004 | -$0.004 |
| EPS | $0.05 | -$0.08 | -$0.001 | -$0.001 |
| Diluted EPS | $0.05 | -$0.08 | -$0.001 | -$0.00 |
| Weighted Avg Shares Outstanding | $2.18B | $2.12B | $2.10B | $2.00B |
| Weighted Avg Shares Outstanding (Diluted) | $2.18B | $2.12B | $2.10B | $2.11B |
The company's financials show resilient growth, with revenue advancing from $224.11M in Q3 2023 to $33.12M in Q4 2024. Gross profit remained healthy with margins at -105% in Q4 2024 compared to 52% in Q3 2023. Operating income hit $160.05M last quarter, sustaining a consistent 483% margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at $188.36M. Net income rose to $3.14B, while earnings per share reached $0.05. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan